Related Experiment Video
Updated: May 17, 2025
11:06
Comparison of Tobacco Host Cell Protein Removal Methods by Blanching Intact Plants or by Heat Treatment of Extracts
Published on: August 8, 2016
9.0K
Autonomous Abiotic Thermal Protectant for Immunoglobulin G: Reducing the Need for Cold Chain Storage
Beverly Chou1, Rishad J Dalal1, Kenneth J Shea1
1Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States.
Biomacromolecules
|April 7, 2025
Summary
A novel thermal protectant (TP) stabilizes biologic therapeutics like immunoglobulin G (IgG) by mimicking heat shock proteins. This nanoparticle technology reduces the need for cold chain storage, improving drug accessibility.
Area of Science:
- Biotechnology
- Materials Science
- Protein Chemistry
Background:
- Biologic therapeutics, particularly antibodies like immunoglobulin G (IgG), are crucial in modern medicine.
- The therapeutic efficacy of antibodies is often compromised by thermal instability, necessitating strict cold chain management.
- Current cold chain requirements increase costs and limit accessibility of these vital treatments.
Purpose of the Study:
- To develop a novel thermal protectant (TP) for stabilizing immunoglobulin G (IgG) without the need for a continuous cold chain.
- To engineer a hydrogel copolymer nanoparticle that mimics the stabilizing function of heat shock proteins.
- To create a temperature-responsive system for antibody stabilization and controlled release.
Main Methods:
- Design and synthesis of a hydrogel copolymer nanoparticle acting as a thermal protectant for IgG.
- Characterization of the nanoparticle's thermal transition and its affinity for IgG at varying temperatures.
- Evaluation of the nanoparticle's ability to prevent IgG aggregation and maintain protein stability at elevated temperatures.
Main Results:
- The developed TP exhibits minimal affinity for IgG below 25 °C.
- An autonomous phase transition around 27 °C enables high affinity binding and sequestration of IgG.
- The TP effectively stabilizes IgG at temperatures significantly above its melting point, preventing aggregation.
- Upon cooling, the TP releases stabilized IgG, allowing for potential refolding into its native state.
Conclusions:
- The novel thermal protectant offers a promising strategy to mitigate the cold chain dependency for biologic therapeutics.
- This temperature-responsive nanoparticle system demonstrates potential for enhancing the stability and shelf-life of antibody-based drugs.
- The technology could significantly reduce logistical challenges and improve global access to essential antibody therapies.
